ROS1 and non-small cell lung carcinoma: Although the incidence of ROS1 rearrangement in NSCLC is rare, it has been found to be targetable by treatment with a tyrosine kinase inhibitor such as crizotinib, which was FDA- and EMA-approved as a first-line agent in 2016 [2].